AT329579T - Solid dispersion with ritonavir, fenofibrate or griseofulvin - Google Patents

Solid dispersion with ritonavir, fenofibrate or griseofulvin

Info

Publication number
AT329579T
AT329579T AT00979161T AT00979161T AT329579T AT 329579 T AT329579 T AT 329579T AT 00979161 T AT00979161 T AT 00979161T AT 00979161 T AT00979161 T AT 00979161T AT 329579 T AT329579 T AT 329579T
Authority
AT
Austria
Prior art keywords
griseofulvin
fenofibrate
ritonavir
solid dispersion
dispersion
Prior art date
Application number
AT00979161T
Other languages
German (de)
Inventor
Steven K Krill
James J Fort
Devalina Law
Eric A Schmitt
Yihong Qiu
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US43899499A priority Critical
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AT329579T publication Critical patent/AT329579T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
AT00979161T 1999-11-12 2000-11-10 Solid dispersion with ritonavir, fenofibrate or griseofulvin AT329579T (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US43899499A true 1999-11-12 1999-11-12

Publications (1)

Publication Number Publication Date
AT329579T true AT329579T (en) 2006-07-15

Family

ID=23742853

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00979161T AT329579T (en) 1999-11-12 2000-11-10 Solid dispersion with ritonavir, fenofibrate or griseofulvin

Country Status (7)

Country Link
US (1) US9107830B2 (en)
EP (1) EP1175205B1 (en)
JP (3) JP5767429B2 (en)
AT (1) AT329579T (en)
CA (1) CA2359945C (en)
DE (1) DE60028754T2 (en)
WO (1) WO2001034119A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT329579T (en) * 1999-11-12 2006-07-15 Abbott Lab Solid dispersion with ritonavir, fenofibrate or griseofulvin
US7364752B1 (en) * 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
DE10026698A1 (en) 2000-05-30 2001-12-06 Basf Ag Self-emulsifying drug formulation and use of this formulation
CA2476587C (en) * 2002-02-26 2010-05-04 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
SI21223A (en) * 2002-06-19 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition with stabilised amorphous donepezil,chloride
EP1829541A1 (en) * 2002-12-17 2007-09-05 Abbott GmbH & Co. KG Formulation comprising fenofibric acid or a physiologically acceptable salt thereof
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
AU2013201423B2 (en) * 2003-08-28 2015-11-05 Abbvie Inc. Solid pharmaceutical dosage form
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
EP1680086A2 (en) * 2003-10-10 2006-07-19 LifeCycle Pharma A/S A solid dosage form comprising a fibrate and a statin
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
KR20130103818A (en) * 2003-10-10 2013-09-24 벨로시스 파마슈티컬스 에이/에스 A solid dosage form comprising a fibrate
JP2007512345A (en) * 2003-11-21 2007-05-17 シェーリング コーポレイションSchering Corporation Phosphodiesterase v inhibitor formulation
US20070104740A1 (en) * 2003-12-23 2007-05-10 Voorspoels Jody Firmin M Self-microemulsifying drug delivery systems of a hiv protease inhibitor
WO2005065657A2 (en) 2003-12-31 2005-07-21 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
US7576216B2 (en) 2004-07-30 2009-08-18 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
GB0502790D0 (en) * 2005-02-10 2005-03-16 Univ London Pharmacy Solid dispersion of hydrophobic bioactive
AU2012202831B2 (en) * 2005-02-23 2015-01-22 Abbvie Inc. A solid pharmaceutical dosage formulation
WO2006107411A2 (en) * 2005-03-30 2006-10-12 Teva Pharmaceutical Industries Ltd. Formulations containing fenofibrate and surfacant mixture
AU2005330266A1 (en) * 2005-03-30 2006-10-12 Teva Pharmaceutical Industries Ltd. Improved formulations of fenofibrate containing menthol or PEG/poloxamer
ME02003B (en) * 2005-04-11 2012-12-31 Abbott Lab Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs
WO2007050975A2 (en) * 2005-10-26 2007-05-03 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system as capsule fill
CA2627351C (en) 2005-10-26 2012-05-01 Banner Pharmacaps, Inc. Lipophilic vehicle-based dual controlled release matrix system
EP2391350A1 (en) 2008-12-18 2011-12-07 Ranbaxy Laboratories Limited Atazanavir formulations
JP5850576B2 (en) * 2010-07-06 2016-02-03 富士化学工業株式会社 Bosentan solid dispersion
DK2654731T3 (en) 2010-12-23 2016-11-14 Abbvie Deutschland SOLID Retard-FORMULATIONS BASED ON SOLID DISPERSIONS
US10286056B2 (en) * 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
JP5977062B2 (en) * 2011-03-30 2016-08-24 興和株式会社 Capsules filled with caffeine containing liquid composition and the composition
US9096556B2 (en) 2011-05-27 2015-08-04 Hetero Research Foundation Amorphous ritonavir co-precipitated
KR20160034348A (en) * 2013-07-22 2016-03-29 산도즈 아게 Formulations containing amorphous dapagliflozin
WO2015017466A1 (en) * 2013-07-30 2015-02-05 Gilead Connecticut, Inc. Formulation of syk inhibitors
JP6235924B2 (en) * 2014-02-13 2017-11-22 壽製薬株式会社 Solid dispersion of fenofibrate
WO2018227179A1 (en) * 2017-06-09 2018-12-13 Isp Investments Llc Small-molecule lactams in coamorphous pharmaceutical phases
JP6506810B2 (en) * 2017-10-03 2019-04-24 壽製薬株式会社 Solid dispersion of fenofibrate

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH029007B2 (en) * 1979-07-05 1990-02-28 Yamanouchi Pharma Co Ltd
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
JPS56110612A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Readily disintegrable and absorbable compression molded article of slightly soluble drug
FR2525108B1 (en) * 1982-04-19 1989-05-12 Elan Corp Ltd Drugs has high degree of solubility and process for obtaining them
US4769235A (en) 1984-01-27 1988-09-06 New York University Immunodominant epitope of the circumsporozoite surface protein
JPS61205208A (en) * 1985-03-08 1986-09-11 Yamanouchi Pharmaceut Co Ltd Rapidly solubilizing preparation for hard-soluble medicines
US4590065A (en) 1985-04-18 1986-05-20 Colgate-Palmolive Company Stable flavor-containing dentifrice
JPS61205208U (en) 1985-06-12 1986-12-24
US4758427A (en) 1985-08-08 1988-07-19 Ciba-Geigy Corporation Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
PH22025A (en) 1985-08-19 1988-05-13 Johnson & Son Inc S C Aqueous pyrethroid insecticidal formulations and method of increasing the stability thereof
DE3612212A1 (en) 1986-04-11 1987-10-15 Basf Ag shaping process for the preparation of solid pharmaceutical
DE3612211A1 (en) 1986-04-11 1987-10-15 Basf Ag Continuous method for tableting
DE3682208D1 (en) 1986-12-18 1991-11-28 Kurt Heinz Bauer Opposite light influential stabilized nifedipine-concentrate and process for its production.
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
DE3812567A1 (en) 1988-04-15 1989-10-26 Basf Ag A process for preparing pharmaceutical mixtures
DE3830353A1 (en) 1988-09-07 1990-03-15 Basf Ag shaping process for the continuous preparation of solid pharmaceutical
US5368864A (en) 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
DE3839825C2 (en) * 1988-11-25 1992-04-16 Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin, De
GB8903328D0 (en) 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5696270A (en) 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
HU204529B (en) 1989-08-10 1992-01-28 Richter Gedeon Vegyeszet Process for producing new 1-oxa-2-oxo-8-aza-spiro(4,5)decane derivatives and pharmaceutical compositions containing them
AU648573B2 (en) 1990-06-01 1994-04-28 Research Corporation Technologies, Inc. Self-emulsifying glasses
AT159426T (en) 1991-04-16 1997-11-15 Nippon Shinyaku Co Ltd A process for producing a solid dispersion
DE4138513A1 (en) 1991-11-23 1993-05-27 Basf Ag A solid pharmaceutical sustained-release form
AU671811B2 (en) 1991-12-18 1996-09-12 Warner-Lambert Company A process for the preparation of a solid dispersion
DE4201179A1 (en) 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Granulates or pellets comprising dispersion of active agent in hydrophilic macromolecules - are e.g. for treatment of depression, hypertension, rheumatism, etc.
AU675930B2 (en) 1992-02-18 1997-02-27 Pharmos Corp. Dry compositions for preparing submicron emulsions
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
CA2095776C (en) 1992-05-12 2007-07-10 Richard C. Fuisz Rapidly dispersable compositions containing polydextrose
IT1256026B (en) 1992-06-12 1995-11-20 Salts of glutathione ethyl ester
DE4220782A1 (en) 1992-06-25 1994-01-05 Basf Ag Process for the preparation of solid pharmaceutical sustained release forms
DE4226753A1 (en) 1992-08-13 1994-02-17 Basf Ag Substances containing preparations in the form of solid particles
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
DE69530973T2 (en) 1994-02-16 2004-05-19 Abbott Laboratories, Abbott Park A process for preparing finely divided pharmaceutical formulations
DE4413350A1 (en) 1994-04-18 1995-10-19 Basf Ag Slow-release matrix pellets, and methods for their preparation
FR2722984B1 (en) 1994-07-26 1996-10-18 Effik Lab Method for preparation of dry dosage forms and pharmaceutical compositions thus produced
DE4446468A1 (en) 1994-12-23 1996-06-27 Basf Ag A process for the preparation of coated tablets
DE4446470A1 (en) 1994-12-23 1996-06-27 Basf Ag A process for the production of divisible tablets
DE4446467A1 (en) 1994-12-23 1996-06-27 Basf Ag A process for the production of lenticular tablets by melt
US5545628A (en) 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
NZ270439A (en) * 1995-02-02 1996-04-26 Bernard Charles Sherman Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer
DE19504832A1 (en) 1995-02-14 1996-08-22 Basf Ag Solid drug preparations
DE19509807A1 (en) 1995-03-21 1996-09-26 Basf Ag A process for the preparation of drug formulations in the form of a solid solution of the active ingredient in a polymer matrix, with this method produced active substance preparations
DE19509805A1 (en) 1995-03-21 1996-09-26 Basf Ag Transparent, fast-release formulations of nonsteroidal analgesics
DE19509806A1 (en) 1995-03-21 1996-09-26 Basf Ag Storage stable dosage forms
SI9500173B (en) * 1995-05-19 2002-02-28 Lek, Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
SE9502244D0 (en) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
BE1009856A5 (en) 1995-07-14 1997-10-07 Sandoz Sa Pharmaceutical composition in the form of a solid release including macrolide and a vehicle.
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
DE19531277A1 (en) 1995-08-25 1997-02-27 Basf Ag Use of lipids as aids in the production of solid drug forms by melt extrusion
DE19536394A1 (en) 1995-09-29 1997-04-03 Basf Ag A solid drug form obtainable by extrusion of an isomalt-containing polymer-drug melt
DE19539361A1 (en) 1995-10-23 1997-04-24 Basf Ag A process for producing multilayer, solid drug forms for oral or rectal administration
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
DE19602206A1 (en) 1996-01-23 1997-07-24 Basf Ag Preparations of nonsteroidal analgesics
DE19617716A1 (en) 1996-05-03 1997-11-06 Basf Ag In aqueous solution, re-dispersible polymer powder
DE69726729T2 (en) 1996-05-20 2004-12-02 Janssen Pharmaceutica N.V. Fungicidal agents with improved bioavailability
BR9711167A (en) 1996-05-24 1999-08-17 Schering Corp Com-AEO antifungal with greater bioavailability
US5834472A (en) 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
AU3146997A (en) 1996-06-03 1998-01-05 Merck & Co., Inc. Pediatric formulation for hiv protease inhibitors
DE19624607A1 (en) 1996-06-20 1998-01-02 Basf Ag A process for the preparation of salts of acid group-containing pharmaceutical active substances
DE19635676A1 (en) 1996-09-03 1998-03-05 Basf Ag Solid foamed active ingredient preparations
HRP970485A2 (en) 1996-09-13 1998-08-31 Joerg Rosenberg Process for producing solid pharmaceutical forms
US5727878A (en) 1996-10-17 1998-03-17 Cdf Corporation Liner for a mixing container and an assembly and method for mixing fluid components
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
FR2756736B1 (en) 1996-12-05 1999-03-05 Sanofi Sa Pharmaceutical compositions containing derivatives of N-sulfonyl indoline
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6197787B1 (en) 1997-03-03 2001-03-06 Sanofi-Synthelabo Pharmaceutical formulations containing poorly soluble drug substances
DE19709663A1 (en) 1997-03-10 1998-09-17 Basf Ag Use of redispersible polymer powders or polymer granules as binders for the production of solid pharmaceutical dosage forms
DE19710213A1 (en) 1997-03-12 1998-09-17 Basf Ag A process for producing solid combination drug forms
DE19710009A1 (en) 1997-03-12 1998-09-24 Knoll Ag Multi-phase active ingredient-containing formulations
US5948426A (en) 1997-05-03 1999-09-07 Jefferies; Steven R. Method and article to induce hematopoietic expansion
DE19721467A1 (en) 1997-05-22 1998-11-26 Basf Ag A process for preparing small-scale preparations of biologically active substances
US5955475A (en) 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
JPH1125076A (en) 1997-06-30 1999-01-29 Fujitsu Ltd Document managing device and document management program storage medium
EP0896823B1 (en) 1997-07-15 2002-09-25 Development Center For Biotechnology Improved stabilization of Misoprostol
DE19733505A1 (en) 1997-08-01 1999-02-04 Knoll Ag Fast acting analgesic
CA2302275C (en) 1997-09-19 2009-12-08 Shire Laboratories Inc. Solid solution beadlet
US6027747A (en) 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
AT214595T (en) 1997-11-28 2002-04-15 Knoll Ag A process for preparing solvent-free noncrystalline bioactive substances
US6632455B2 (en) * 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
JPH11271927A (en) * 1998-01-20 1999-10-08 Mitsubishi Paper Mills Ltd Supporting body for image material
US6787157B1 (en) 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
US20040062802A1 (en) 1998-04-02 2004-04-01 Hermelin Victor M. Maximizing effectiveness of substances used to improve health and well being
DE19814730A1 (en) 1998-04-02 1999-10-07 Basf Ag Pharmaceutical and cosmetic compositions with matrix containing N-vinyllactam or N-vinylamine based copolymer
US5945123A (en) 1998-04-02 1999-08-31 K-V Pharmaceutical Company Maximizing effectiveness of substances used to improve health and well being
KR100336090B1 (en) 1998-06-27 2002-05-27 윤승원 Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixture thereof
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
DE19839276A1 (en) 1998-08-28 2000-03-02 Basf Ag A process for the preparation of solid dosage forms
DE19840256A1 (en) 1998-09-03 2000-03-09 Basf Ag Widely applicable, continuous method for preparing coated solid dosage forms, comprises extruding mixture of drug and thermoplastic binder then applying coating composition in liquid or vapor form
DE19841244A1 (en) 1998-09-09 2000-03-16 Knoll Ag Method and apparatus for the manufacture of tablets
DE19842914A1 (en) 1998-09-18 2000-03-23 Basf Ag Test system for the characterization of the compatibility of biologically active substances and polyvinylpyrrolidone
DE19847618A1 (en) 1998-10-15 2000-04-20 Basf Ag Production of solid dosage forms, used for e.g. pharmaceuticals or insecticides, by preparation of plastic mixture from polymeric binder and active agent under controlled conditions
US6502135B1 (en) 1998-10-30 2002-12-31 Science Applications International Corporation Agile network protocol for secure communications with assured system availability
DE19853985A1 (en) 1998-11-23 2000-05-25 Basf Ag Producing solid dosage form, using molding calender of two cylinders with specific surface structures, avoids problems of misalignment of upper and lower halves of the product
DE19855440A1 (en) 1998-12-01 2000-06-08 Basf Ag A method for producing solid dosage forms by melt extrusion
DE19856147A1 (en) 1998-12-04 2000-06-08 Knoll Ag Divisible solid dosage forms and methods for their preparation
DE19901383A1 (en) 1999-01-15 2000-07-20 Knoll Ag A process for preparing various solid dosage forms
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
DE19911097A1 (en) 1999-03-12 2000-09-14 Basf Ag A process for the preparation of solid dosage forms cyclodextrin-
DE19913692A1 (en) 1999-03-25 2000-09-28 Basf Ag Mechanically stable pharmaceutical dosage forms containing liquid or semisolid surface-active substances
DE19913606A1 (en) 1999-03-25 2000-09-28 Basf Ag Powdered Solubilisationshilfsstoffe for solid pharmaceutical dosage forms
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
FR2793689B1 (en) 1999-05-19 2001-08-24 Pf Medicament A transdermal device for administering testosterone or its derivatives
US6465011B2 (en) 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
IL146025D0 (en) 1999-06-04 2002-07-25 Abbott Lab Improved pharmaceutical formulations comprising at least one hiv protease inhibiting compound
DE19929361A1 (en) 1999-06-25 2001-01-04 Basf Ag Mechanically stable pharmaceutical dosage forms containing liquid or semisolid surface-active substances
DE19930454A1 (en) 1999-07-02 2001-01-04 Knoll Ag Solid paroxetine-containing preparations
HU228449B1 (en) 1999-09-24 2013-03-28 Janssen Pharmaceutica Nv Antiviral compositions
DE19945982A1 (en) 1999-09-24 2001-03-29 Knoll Ag Certain speed particles
PT1227797E (en) 1999-11-12 2005-05-31 Abbott Lab Pharmaceutical formulations of solid dispersion
AT329579T (en) 1999-11-12 2006-07-15 Abbott Lab Solid dispersion with ritonavir, fenofibrate or griseofulvin
US7364752B1 (en) * 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19960494A1 (en) 1999-12-15 2001-06-21 Knoll Ag Device and method for producing solid active substance-containing forms
CZ20022047A3 (en) 1999-12-23 2003-09-17 Pfizer Products Inc. Pharmaceutical compositions providing increased concentration of a medicament
NZ519724A (en) 2000-01-19 2004-07-30 Abbott Lab Chad 0377 Ap6D 2 A combination solubilised HIV protease inhibiting compound, a medium and or long clain fatty acid and an alcohol that has improved solubility properties
DE10013289A1 (en) 2000-03-17 2001-09-20 Knoll Ag Storage-stable formulations containing diuretic torasemide, are solids or semi-solids containing the active agent in non-crystalline form, e.g. as solid solution in vinyl pyrrolidone polymer matrix
US6608198B2 (en) 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical
DE10026698A1 (en) 2000-05-30 2001-12-06 Basf Ag Self-emulsifying drug formulation and use of this formulation
DE10026699A1 (en) 2000-05-30 2001-12-06 Basf Ag Formulation heparin, glycosaminoglycan or Heparinoidbasis and use of the formulation and the formulation base
WO2002002081A1 (en) 2000-07-05 2002-01-10 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and methods of using same
DE10038571A1 (en) 2000-08-03 2002-02-14 Knoll Ag Compositions and dosage forms for use in the oral cavity in the Bhandlung mycoses
WO2002020057A2 (en) 2000-09-05 2002-03-14 Abbott Laboratories Flavoring systems for pharmaceutical compositions and methods of making such compositions
DE10046541A1 (en) 2000-09-19 2002-03-28 Knoll Ag Oral dosage form useful as nutritional supplement or medicament comprises solid dispersion of ubiquinone in thermoplastic matrix
US6579521B2 (en) 2000-10-20 2003-06-17 Chiron Corporation Methods of therapy for HIV infection
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
EA006627B1 (en) 2001-05-03 2006-02-24 Ф.Хоффманн-Ля Рош Аг The pharmaceutical dosage form of amorphous nelfinavir mesylate
AP1652A (en) 2001-05-11 2006-08-11 Tibotec Pharm Ltd
WO2002096395A1 (en) 2001-05-25 2002-12-05 Abbott Laboratories Soft elastic capsules comprising ritonavir and/or lopinavir
WO2002096392A1 (en) 2001-05-31 2002-12-05 Cima Labs Inc. Taste-masking of highly water-soluble drugs
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
EA200301250A1 (en) 2001-06-22 2004-06-24 Пфайзер Продактс Инк. PHARMACEUTICAL COMPOSITIONS, CONTAINING LOW-Soluble And / Or Acid-Sensitive Drugs and Neutralized Acid Polymers
AT361758T (en) 2001-06-22 2007-06-15 Pfizer Prod Inc Pharmaceutical compositions comprising a solid dispersion of a sparingly soluble in water drug and a polymer löslichkeitsteigerndes
JP2004534812A (en) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク The pharmaceutical composition of the dispersion of drug and neutral polymer
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
CA2452330C (en) 2001-07-06 2011-03-22 Lifecycle Pharma A/S Controlled agglomeration
EP1419111A1 (en) 2001-07-09 2004-05-19 Shell Internationale Research Maatschappij B.V. Inhibiting scale deposition in oilfield tubulars
DE10133570C1 (en) 2001-07-13 2002-09-05 Octel Corp Purification of water, especially ground water, contaminated with lead alkyls, especially lead methyl and lead ethyl, comprises passing water through organic cation exchanger
JP2003068576A (en) * 2001-08-30 2003-03-07 Rohm Co Ltd Structure of surface mounted solid electrolytic capacitor and manufacturing method therefor
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
MXPA04007438A (en) 2002-02-01 2004-10-11 Pfizer Prod Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials.
DE10213242A1 (en) 2002-03-25 2003-10-16 Abbott Gmbh & Co Kg Test system for evaluating the compatibility of biologically active substances with copolymers
IL165383D0 (en) 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
CN100515388C (en) 2002-06-26 2009-07-22 拓 金 Solid dosage forms for rapid dissolution of poorly soluble drugs
AR039744A1 (en) 2002-06-26 2005-03-09 Alza Corp Methods and dosage forms to increase solubility of drug compositions for controlled administration
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
CA2496441C (en) 2002-08-12 2010-03-16 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
WO2005000265A2 (en) 2002-09-11 2005-01-06 Elan Pharma International Ltd. Gel-stabilized nanoparticulate active agent compositions
DE10247037A1 (en) 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Solid, rapid release dosage form, especially for sparingly soluble drugs, obtained by forming and cooling softened, shapable mixture of crosslinked non-thermoplastic carrier, adjuvant and active agent
DE10250711A1 (en) 2002-10-31 2004-05-19 Degussa Ag Pharmaceutical and cosmetic preparations
WO2004050068A1 (en) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP1572190B1 (en) 2002-12-17 2007-04-18 Abbott GmbH & Co. KG Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20040258752A1 (en) 2003-01-31 2004-12-23 Paruthi Manoj Kumar Taste masking pharmaceutical composition and process for its preparation
US20040185170A1 (en) 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
KR101511196B1 (en) 2003-05-28 2015-04-10 노바르티스 아게 Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agent microparticle with a partial or complete amino acid and/or phospholipid coat
RS20060009A (en) 2003-07-11 2008-06-05 F.Hoffmann-La Roche Ag., Saquinavir mesylate oral dosage form
DE10332160A1 (en) 2003-07-15 2005-02-03 Röhm GmbH & Co. KG A multiparticulate pharmaceutical form comprising mucoadhesively formulated peptide or protein active ingredients, and a process for preparing the drug form
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
ES2452733T3 (en) 2004-05-28 2014-04-02 Abbvie Deutschland Gmbh & Co Kg Dosage form obtainable from a powder mixture comprising an inorganic pigment
JP2009530382A (en) 2006-03-23 2009-08-27 シェーリング コーポレイションSchering Corporation Combination of Hcv protease inhibitors and cyp3a4 inhibitor, and related methods of treatment

Also Published As

Publication number Publication date
DE60028754T2 (en) 2007-05-31
EP1175205A2 (en) 2002-01-30
CA2359945A1 (en) 2001-05-17
JP6122087B2 (en) 2017-04-26
US20070249692A1 (en) 2007-10-25
CA2359945C (en) 2011-04-26
JP2013224297A (en) 2013-10-31
JP2016065073A (en) 2016-04-28
US9107830B2 (en) 2015-08-18
JP2003513904A (en) 2003-04-15
DE60028754D1 (en) 2006-07-27
JP5767429B2 (en) 2015-08-19
EP1175205B1 (en) 2006-06-14
WO2001034119A3 (en) 2001-11-22
JP5873043B2 (en) 2016-03-01
WO2001034119A9 (en) 2002-09-26
WO2001034119A2 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
DE60029251D1 (en) MPEG-ummultiplexer with multiple inputs and multiple outputs
DE60037299D1 (en) Elektrolumineszensanzeige active matrix
DE60001530D1 (en) Interconnects
DE59802554D1 (en) The security document
DE60020688D1 (en) Polymeric composition and pressure or photocopiers transfer sheet that, this composition contains
DE122007000065I2 (en) 3,3-diphenylpropylaminderivate
DE60029426D1 (en) Convertible catheter with multiple size
NO326456B1 (en) Bronnhullsverktoy with extendable members
AT498158T (en) The reconfigurable processing system, and - procedures
DE60044719D1 (en) Inhaler with threshold-valve
TR199801629A3 (en) 2 -metoksibenzofenon and fungicidal.
AT400831T (en) Microfabricated mirror-device
NO318909B1 (en) Novel compounds and their use, and pharmaceutical preparations.
DE69934345D1 (en) Self-filling needle-free Y-adapter
DE60040782D1 (en) Human liver-precursor cells
DE60036874D1 (en) Pellet formulation with controlled release
NO320909B1 (en) Pyrimidine compounds and their use and the preparation thereof and pharmaceutical compositions.
DE60038162D1 (en) Celecoxib in solid form with increased bioavailability
RU2002111569A (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use
NO322297B1 (en) Substituted bisycliske derivatives, their use and pharmaceutical compositions.
AT108873T (en) Toughened-backlash nut.
FI19992555A (en) Antibacterial oksatosolidinoniaineita with tiokarbonyylifunktionaalisuus
FI991068A (en) The antenna structure
AT282455T (en) The catheter
FI991359A (en) The antenna structure

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties